ScinoPharm Taiwan has received US FDA approval for its Glatiramer Acetate (GA) Injection, a complex generic for multiple sclerosis (MS). This milestone positions the company as the first Taiwanese manufacturer to clear the high regulatory bar for Non-Biological Complex Drugs (NBCDs), opening a pathway to the $710 million US market segment and signaling new sourcing options for overseas distributors and clinics.
Market signal
The global GA market was valued at $1.5 billion in 2024 and is projected to reach $2.8 billion by 2033, driven by an estimated 2.9 million MS patients worldwide, including nearly 1 million in the US. ScinoPharm's approval targets a $710 million slice of this expanding market, offering a new supply source for injectable MS therapies.
Regulatory milestone
Since GA's debut in 1996, it has been recognized as one of the most challenging generics to develop. The FDA classifies it under Non-Biological Complex Drugs (NBCDs), requiring rigorous verification of process reproducibility, quality consistency, and bioequivalence beyond standard generics. ScinoPharm's success marks Taiwan's entry into high-barrier global pharmaceutical competition.
Manufacturing excellence
ScinoPharm employed dozens of advanced analytical techniques and statistical methods to ensure stable parameters for the highly diverse synthesis products. Quality was validated through bioactivity assays identical to the reference drug, demonstrating manufacturing capability that meets stringent US FDA standards.
What buyers should watch
For overseas importers, distributors, and clinic buyers, this approval introduces a new, FDA-approved source for GA injection, potentially expanding supply chain options and competitive pricing. The high regulatory barrier means ScinoPharm's product meets rigorous quality benchmarks, making it a viable alternative for clinics and distributors seeking reliable MS treatment supplies.
Source: Read the original report | Published: June 16, 2026